$11.03
0.00% yesterday
Nasdaq, Jul 14, 10:00 pm CET
ISIN
US92539P1012
Symbol
VERV

Verve Therapeutics Inc Stock price

$11.03
+4.76 75.92% 1M
+5.78 110.10% 6M
+5.39 95.57% YTD
+3.87 54.05% 1Y
-13.17 54.42% 3Y
-20.89 65.44% 5Y
-20.89 65.44% 10Y
-20.89 65.44% 20Y
Nasdaq, Closing price Mon, Jul 14 2025
+0.00 0.00%
ISIN
US92539P1012
Symbol
VERV
Sector
Industry

Key metrics

Basic
Market capitalization
$983.3m
Enterprise Value
$486.2m
Net debt
positive
Cash
$497.1m
Shares outstanding
88.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
16.5 | 20.6
EV/Sales
8.2 | 10.2
EV/FCF
negative
P/B
2.1
Financial Health
Equity Ratio
76.2%
Return on Equity
-40.3%
ROCE
-37.1%
ROIC
-225.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$59.6m | $47.6m
EBITDA
$-201.6m | $-272.4m
EBIT
$-208.5m | $-254.3m
Net Income
$-181.0m | $-225.8m
Free Cash Flow
$-147.0m
Growth (TTM | estimate)
Revenue
271.4% | 47.3%
EBITDA
6.5% | -22.8%
EBIT
6.0% | -11.2%
Net Income
8.0% | -13.6%
Free Cash Flow
1.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-338.2% | -572.0%
EBIT
-349.7%
Net
-303.6% | -474.1%
Free Cash Flow
-246.6%
More
EPS
$-2.0
FCF per Share
$-1.7
Short interest
23.9%
Employees
255
Rev per Employee
$130.0k
Show more

Is Verve Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Verve Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Verve Therapeutics Inc forecast:

6x Buy
43%
8x Hold
57%

Analyst Opinions

14 Analysts have issued a Verve Therapeutics Inc forecast:

Buy
43%
Hold
57%

Financial data from Verve Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
60 60
271% 271%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 58 58
12% 12%
97%
- Research and Development Expense 210 210
13% 13%
353%
-202 -202
7% 7%
-338%
- Depreciation and Amortization 6.84 6.84
15% 15%
11%
EBIT (Operating Income) EBIT -208 -208
6% 6%
-350%
Net Profit -181 -181
8% 8%
-304%

In millions USD.

Don't miss a Thing! We will send you all news about Verve Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verve Therapeutics Inc Stock News

Positive
The Motley Fool
25 days ago
Shares in Verve Therapeutics (VERV -0.54%) soared 80.5% this week on the news of an agreement for Eli Lilly (LLY -2.60%) to acquire Verve. The deal centers on an exciting cardiovascular health medicine program, VERVE-102.
Neutral
Business Wire
26 days ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verve Therapeutics, Inc. (NasdaqGS: VERV) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Verve will receive $10.50 per share in cash, plus one non-tra...
Neutral
Business Wire
28 days ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verve Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareholders. Under the terms of the proposed transaction, Verve shareholders will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive...
More Verve Therapeutics Inc News

Company Profile

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan, and Burt A. Adelman in 2018 and is headquartered in Cambridge, MA.

Head office United States
CEO Sekar Kathiresan
Employees 255
Founded 2018
Website www.vervetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today